ABVC BioPharma, Inc.

ABVC is an early-stage biotechnology company focused on developing new drugs and one medical device. The company has a pipeline of seven new drugs and one medical device under development, all licensed from related parties. ABVC aims to provide therapeutic solutions for unmet medical needs and improve human health by developing innovative botanical drugs to treat central nervous system (CNS) and oncology/hematology diseases. As of the date of this report, ABVC's revenue is generated from outlicensing its intellectual properties and providing CDMO services. The company develops its product pipeline by tracking new medical discoveries or medical device technologies in research institutions within the Asia-Pacific region. ABVC's scientists and specialists examine pre-clinical, disease animal model, and Phase I safety studies to identify drugs or medical devices that demonstrate efficacy and safety based on internal qualifications. Once a drug or medical device is deemed a good candidate for further development and commercialization, ABVC licenses it from the original researchers and introduces the clinical trial plan to principal investigators in the United States, Australia, and Taiwan.